Education
About Us
Working with TipRanks
Follow Us
Bridgebio Pharma (BBIO)
:BBIO
Total Valuation
BridgeBio Pharma has a market cap or net worth of $13.88B. The enterprise value is $12.03B.
Market Cap$13.88B
Enterprise Value$12.03B
Share Statistics
BridgeBio Pharma has 192,708,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding192,708,820
Owned by Insiders20.93%
Owned by Institutions8.91%
Financial Efficiency
BridgeBio Pharma’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is -76.78%.
Return on Equity (ROE)0.37
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-76.78%
Return on Capital Employed (ROCE)-0.78
Revenue Per Employee306.07K
Profits Per Employee-749.44K
Employee Count725
Asset Turnover0.24
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BridgeBio Pharma is ―. BridgeBio Pharma’s PEG ratio is 0.35.
PE Ratio―
PS Ratio23.01
PB Ratio-3.50
Price to Fair Value-3.50
Price to FCF-9.79
Price to Operating Cash Flow-21.79
PEG Ratio0.35
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 221.90M and earned -535.76M in profits. Earnings per share was -2.88.
Revenue221.90M
Gross Profit218.02M
Operating Income-592.97M
Pretax Income-542.19M
Net Income-535.76M
EBITDA-436.83M
Earnings Per Share (EPS)-2.88
Cash Flow
In the last 12 months, operating cash flow was -584.82M and capital expenditures -10.40M, giving a free cash flow of -595.21M billion.
Operating Cash Flow-584.82M
Free Cash Flow-595.21M
Free Cash Flow per Share-3.09
Dividends & Yields
BridgeBio Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change170.71%
50-Day Moving Average59.37
200-Day Moving Average45.16
Relative Strength Index (RSI)71.93
Average Volume (3m)2.52M
Important Dates
BridgeBio Pharma upcoming earnings date is Feb 19, 2026, After Close (Confirmed).
Last Earnings DateOct 29, 2025
Next Earnings DateFeb 19, 2026
Ex-Dividend Date―
Financial Position
BridgeBio Pharma as a current ratio of 4.67, with Debt / Equity ratio of -0.45%
Current Ratio4.67
Quick Ratio4.67
Debt to Market Cap0.34
Net Debt to EBITDA-2.40
Interest Coverage Ratio-5.97
Taxes
In the past 12 months, BridgeBio Pharma has paid 1.15M in taxes.
Income Tax1.15M
Effective Tax Rate>-0.01
Enterprise Valuation
BridgeBio Pharma EV to EBITDA ratio is -14.09, with an EV/FCF ratio of -11.80.
EV to Sales27.74
EV to EBITDA-14.09
EV to Free Cash Flow-11.80
EV to Operating Cash Flow-11.82
Balance Sheet
BridgeBio Pharma has $645.94M in cash and marketable securities with $8.72M in debt, giving a net cash position of $637.22M billion.
Cash & Marketable Securities$645.94M
Total Debt$8.72M
Net Cash$637.22M
Net Cash Per Share$3.31
Tangible Book Value Per Share-$7.96
Margins
Gross margin is 95.78%, with operating margin of -267.22%, and net profit margin of -241.44%.
Gross Margin95.78%
Operating Margin-267.22%
Pretax Margin-244.34%
Net Profit Margin-241.44%
EBITDA Margin-196.86%
EBIT Margin-199.59%
Analyst Forecast
The average price target for BridgeBio Pharma is $83.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$83.13
Price Target Upside15.44% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast62.46%
EPS Growth Forecast-73.59%